Free Daily Headlines :

  • COVID-19
  • Vaccine Info
  • Money
  • Politics
  • Education
  • Health
  • Justice
  • More
    • Environment
    • Economic Development
    • Gaming
    • Investigations
    • Social Services
    • TRANSPORTATION
  • Opinion
    • CT Viewpoints
    • CT Artpoints
DONATE
Reflecting Connecticut’s Reality.
    COVID-19
    Vaccine Info
    Money
    Politics
    Education
    Health
    Justice
    More
    Environment
    Economic Development
    Gaming
    Investigations
    Social Services
    TRANSPORTATION
    Opinion
    CT Viewpoints
    CT Artpoints

LET�S GET SOCIAL

Show your love for great stories and out standing journalism

Blumenthal says Lilly’s Lispro is a ‘bait and switch’ insulin for diabetics

  • Health
  • by Ana Radelat
  • January 3, 2020
  • View as "Clean Read" "Exit Clean Read"

Marco Verch | Flickr

The cost of insulin has skyrocketed since the 1990s, making the life-saving drug inaccessible to many diabetics.

Washington – When Sens. Richard Blumenthal and Elizabeth Warren surveyed the nation’s pharmacies, they found most of them failed to stock a lower-cost “authorized generic” form of insulin that could help many of the nation’s diabetics.

The Democratic senators also revealed the weaknesses in a drug industry tactic of selling a cheaper form of their brand name drug in the hopes of blunting public outrage over the high cost of medicine.

Last March, under political pressure to cut the price of the life-saving drug, Eli Lilly pledged to distribute a generic form of its brand name, $300-per-vial insulin drug, Humalog, at half the price.

At the end of the year, Blumenthal, D-Conn., and Warren, D-Mass., found that Lispro was not available in 83% of the pharmacies surveyed and many pharmacists were unaware of, or not adequately informing their customers, about the availability of the lower-cost Lispro. The senators had commissioned a survey, by telephone, by their staffs of nearly 400 pharmacies.

“It’s a bait-and-switch,” Blumenthal said. “Eli Lilly boasted about its generic and failed to make it available.”

Sen. Richard Blumenthal accused Eli Lilly of a ‘bait and switch’ with Lispro, the company’s generic insulin.

Eli Lilly said Lispro was used by more than 67,000 Americans in November, and 50,000 in October. That’s a fraction of the 7.4 million Americans with diabetes who use some form of insulin, which keeps a diabetic’s blood sugar level from getting too high or too low.

The drug company says more Americans are not using Lispro because pharmacy benefits managers and health insurance companies don’t prioritize access to lower-cost drugs, preferring instead the rebates they receive from drug manufacturers such as Lilly for more expensive brand-name drugs.

“Like Senators Warren and Blumenthal, Lilly would like to see even broader use of Insulin Lispro because it’s a real solution that lowers co-pays for people living with diabetes,” the company said. “But the senators’ paper fails to identify the system challenges that have inhibited access of this new lower list price option.”

Unlike true generics, which are produced by competing drug companies, authorized generics are sold by the original manufacturer at a discounted price.  The authorized generic has marketing exclusivity until the original brand drug loses its patent, which means the drug maker maintains its monopoly for that drug.

The Food and Drug Administration has a list of more than 1,200 authorized generic drugs, including Zoloft, Lipitor and Lopressor.

In the case of insulin, a drug that was first produced 100 years ago, drug manufacturers have kept their patents and generic companies at bay by making small changes to their products.

Three pharmaceutical companies — Sanofi, Novo Nordisk, and Eli Lilly — dominate the insulin market, producing more than 80% of the global insulin supply.

“These companies have taken advantage of limited market competition by steadily hiking insulin prices, even though experts estimate insulin could be profitably produced for $7 to $11 per patient per month,” the Blumenthal-Warren report said. “The cost of insulin has risen by over 1,200 percent since the 1990s.”

The report said that at least 12 Americans have died as a result of rationing insulin in the past three years, and roughly one in four patients with diabetes have reported skipping doses or rationing their intake due to the high price of the drug.

On average, diabetics use two to four vials per month, meaning those without insurance face costs of more than $1,000 per month without rebates or discounts.

And those with insurance may face steep co-pays.

Eli Lilly said insurers are using rebates from drug companies to lower premiums for all of their customers instead of lowering co-pays for chronic medicines like insulin.

“It’s why payers prefer higher list priced, higher rebated products,” Eli Lilly spokesman Gregory Andrew Kueterman said.

He also said wholesalers and pharmacies “solely decide whether to distribute or stock Insulin Lispro.”

Sen. Elizabeth Warren and Sen. Richard Blumenthal found a weak marketplace for Eli Lilly’s generic insulin.

“They are well aware and have access to Insulin Lispro,” Kuterman said.

Blumenthal dismissed the pharmaceutical company’s argument.

“Eli Lilly is blaming everyone but itself,” he said.

He said he and other Democrats will keep pressing Eli Lilly and other makers of insulin to drop their prices.

“Insulin is a life-saving drug that is necessary for survival, ” Blumenthal said. “It’s not a luxury or convenience folks can live without.”

Meanwhile, America’s Health Insurance Plans, a health insurer trade group, said the promotion of authorized generics like Lispro is “a distraction” that does not result in any savings to consumers.

“Now the Big Pharma company has two drugs on the market – the original, high-priced brand, and the lower-cost generic alternative,” said AHIP spokeswoman Catherine Donaldson. “It still has the corner on the market. And it wins regardless of which drug the consumer chooses.”

She said she appreciated that an authorized generic offers a lower-priced alternative.

“But why not simply drop the price of the branded drug so everyone can save?” Donaldson asked.

In Canada, insulin is sold at about one-tenth of the list price in the United States. Last month, the Trump administration proposed regulations that would allow states to import cheaper prescription drugs from Canada – but it excluded insulin and other complex biologic drugs.

Congress has also faltered in its attempts to rein in the costs of pharmaceuticals, which continue to rise.

On New Year’s Day, Bristol Myers Squibb, Gilead Sciences, Biogen and other drugmakers increased list prices on 50 drugs, by a median of about 5%. Additional price increases are expected in the following weeks.

Sign up for CT Mirror's free daily news summary.

Free to Read. Not Free to Produce.

The Connecticut Mirror is a nonprofit newsroom. 90% of our revenue comes from people like you. If you value our reporting please consider making a donation. You'll enjoy reading CT Mirror even more knowing you helped make it happen.

YES, I'LL DONATE TODAY

ABOUT THE AUTHOR

Ana Radelat Ana has written about politics and policy in Washington, D.C.. for Gannett, Thompson Reuters and UPI. She was a special correspondent for the Miami Herald, and a regular contributor to The New York TImes, Advertising Age and several other publications. She has also worked in broadcast journalism, for CNN and several local NPR stations. She is a graduate of the University of Maryland School of Journalism.

SEE WHAT READERS SAID

RELATED STORIES
Plan to expand child tax credit offers hope along with direct payments
by Lisa Backus | C-HIT.ORG

When her car started making a noise more than a year ago, Chinara Johnson parked the vehicle and hasn’t used it since. As a New Haven mother of 5-year-old twin boys, one of whom is on the autism spectrum, and an 8-year-old daughter, Johnson doesn’t have the money to get the car running properly again. […]

Republicans on key committee oppose no-excuse absentee ballot voting
by Mark Pazniokas

Republicans signaled Friday they will try to block fast-track action on a constitutional amendment allowing no-excuse voting by absentee ballot.

Aid-in-dying bill clears key hurdle with committee passage
by Jenna Carlesso

The bill would let terminally ill patients access medication to end their lives.

Ned Lamont’s year in the shadow of COVID
by Mark Pazniokas

Ned Lamont has been the face, voice, and interpreter of the COVID crisis, mourning deaths, explaining setbacks and cautiously celebrating.

With billions in federal relief on the way to CT, legislators assert their role in deciding how to spend it
by Keith M. Phaneuf and Mark Pazniokas

With an unusual bill, state legislators are reminding Gov. Ned Lamont they have significant role in disbursing federal coronavirus relief.

Support Our Work

Show your love for great stories and outstanding journalism.

$
Select One
  • Monthly
  • Yearly
  • Once
Artpoint painter
CT ViewpointsCT Artpoints
Opinion The public health bill no one is talking about, but should be
by Brian Festa

On February 16,  the legislature's Public Health Committee conducted a public hearing on two bills, S.B. 568 and H.B. 6423, both of which would eliminate the religious exemption to mandatory vaccinations for Connecticut schoolchildren.  The hearing was capped at 24 hours, depriving nearly 1,500 members of the public who had registered for the hearing their opportunity to be heard.  The vast majority of those who did testify, and who submitted written testimony, opposed the bill.  The committee is expected to vote on the bill as early as  today. 

Opinion Students need more resources, fewer officers
by Tenille Bonilla

"School resource officer" is just a nice way to say cop. But what students really need is more resource and less officer.

Opinion The Board of Regents’ changes must not shortchange its students or faculty
by Carrie Andreoletti, PhD

As a university professor and a lifespan developmental psychologist, I tend to approach my work from a developmental perspective. This means I aim to foster a lifelong love of learning and to help others find a sense of meaning and purpose, as well as confidence in their ability to reach their goals. My approach to higher education is shaped by my desire to provide the best possible education for my students. This is why the recent Board of Regents’ proposed changes at the four state universities have me worried.

Opinion How to close schooling opportunity gaps created by the pandemic
by Carol Gale

We ask school district leaders to trust your public servants whose daily work life involves assessing student needs and planning or modifying instruction to meet those needs. Listen to their voices, as we have, and allocate precious resources on interventions that will offer increased opportunities for Hartford students to succeed.

Artwork Grand guidance
by Anne:Gogh

In a world of systemic oppression aimed towards those of darker skintones – representation matters. We are more than our equity elusive environments, more than numbers in a prison and much more than victims of societal dispositions. This piece depicts a melanated young man draped in a cape ascending high above multiple forms of oppression. […]

Artwork Shea
by Anthony Valentine

Shea is a story about race and social inequalities that plague America. It is a narrative that prompts the question, “Do you know what it’s like to wake up in new skin?”

Artwork The Declaration of Human Rights
by Andres Chaparro

Through my artwork I strive to create an example of ideas that reflect my desire to raise social consciousness, and cultural awareness. Jazz music is the catalyst to all my work, and plays a major influence in each piece of work.”

Artwork ‘A thing of beauty. Destroy it forever’
by Richard DiCarlo | Derby

During times like these it’s often fun to revisit something familiar and approach things with a different slant. I have been taking some Pop culture and Art masterpieces and applying the vintage 1960’s and 70’s classic figures (Fisher Price, little people) to the make an amusing pieces. Here is my homage to Fisher -Price, Yellow […]

Twitter Feed
A Twitter List by CTMirror

Engage

  • Reflections Tickets & Sponsorships
  • Events
  • Donate
  • Newsletter Sign-Up
  • Submit to Viewpoints
  • Submit to ArtPoints
  • Economic Indicator Dashboard
  • Speaking Engagements
  • Commenting Guidelines
  • Legal Notices
  • Contact Us

About

  • About CT Mirror
  • Announcements
  • Board
  • Staff
  • Sponsors and Funders
  • Donors
  • Friends of CT Mirror
  • History
  • Financial
  • Policies
  • Strategic Plan

Opportunity

  • Advertising and Sponsorship
  • Speaking Engagements
  • Use of Photography
  • Work for Us

Go Deeper

  • Steady Habits Podcast
  • Economic Indicator Dashboard
  • Five Things

The Connecticut News Project, Inc. 1049 Asylum Avenue, Hartford, CT 06105. Phone: 860-218-6380

© Copyright 2021, The Connecticut News Project. All Rights Reserved. Website by Web Publisher PRO